The February issue of the Minority Microbiology Mentor has been published by the Committee on Microbiological Issues Impacting Minorities.
The February issue of the e-Public Policy Update has been published by the Office of Public Affairs.
The January/February issue of the Clinical Microbiology Issues Update has been published by the Office of Public Affairs.
January 28, 2015 - ASM Statement on the President’s Proposed 2016 Budget to Combat Antibiotic-Resistant Bacteria
The ASM released a statement on the President’s Proposed 2016 Budget to Combat Antibiotic-Resistant Bacteria.
The ASM sent a letter to Senator Richard Durbin (D-IL) endorsing the bill which would provide a five percent increase in funding for biomedical research supported by the National Institutes of Health and other federal agencies involved in biomedical research.
The ASM sent a letter to members of Congress supporting passage of an FY 2015 Omnibus Appropriations bill to provide sustained and predictable federal funding for life science research and public health programs.
The ASM sent a letter to members of Congress supporting the Administration's $6.18 billion emergency funding request to combat the Ebola Virus outbreak.
October 29, 2014 - ASM Statement on CDC Interim Guidance on Monitoring and Movement of Persons with Suspected Ebola Contact
The ASM issued a statement regarding the Centers for Disease Control and Prevention new Interim Guidance on Monitoring and Movement of Persons with Suspected Ebola Contact.
October 28, 2014 - White House Office of Science and Technology Policy Challenge to Develop Ebola Tools
The ASM sent a message to members about a White House Office of Science and Technology Policy program that solicits the global community to share innovative ideas that deliver practical and cost-effective innovations to address this crisis, to improve delivery of care, and stem the spread of Ebola virus disease.
The White House Office of Science and Technology Policy announced that the U.S. government will undertake a deliberative process to assess the risks and benefits of certain gain-of-function (GOF) experiments with influenza, SARS, and MERS viruses in order to develop a new Federal policy regarding the funding of this research.